Crestline Management’s Abiomed Inc ABMD Stock Holding History

Crestline Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,779	Closed	-$877K	–	138
2016 Q4	$877K	Buy	+7,779	New	+$901K	0.22%	30

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Crestline Management's ABMD Position: Q1 2017 in Review

Crestline Management sold out of Abiomed Inc (ABMD) in Q1 2017, closing a stake of 7,779 shares — an estimated $877K sold.

Crestline Management first reported a position in ABMD in Q4 2016 and held it in 1 quarter. The position peaked at $877K in Q4 2016. 287 funds tracked by Wall St. Rank hold ABMD as of Q1 2017.

Crestline Management reported no remaining Abiomed Inc position as of Q1 2017 after selling out during the quarter.
Crestline Management sold 7,779 Abiomed Inc shares in Q1 2017, an estimated $877K.
Crestline Management first reported a position in Abiomed Inc in Q4 2016 and held it in 1 quarter.
Crestline Management's Abiomed Inc position peaked at $877K in Q4 2016.
287 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2017.

Based on Crestline Management's 13F filing for Q1 2017, filed 12 May 2017.